KalVista Pharmaceuticals, Inc.
NGM: KALVLive Quote
📈 ZcoreAI Score
Our AI model analyzes KalVista Pharmaceuticals, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get KALV Z-Score →About KalVista Pharmaceuticals, Inc.
Healthcare
Biotechnology
KalVista Pharmaceuticals, Inc., a biopharmaceutical company, develops oral therapies for individuals for rare diseases with unmet needs. Its lead product candidate is EKTERLY, a fast-acting potent inhibitor of plasma kallikrein for the treatment of acute attacks of hereditary angioedema (HAE). The company is also developing is developing an orally disintegrating tablet formulation; KONFIDENT-KID for pediatric use with HAE; KONFIDENT; and KONFIDENT-S to evaluate sebetralstat and ODT formulation in adolescent and adult patients. KalVista Pharmaceuticals, Inc. is headquartered in Framingham, Massachusetts.
📊 Fundamental Analysis
KalVista Pharmaceuticals, Inc. demonstrates a profit margin of -223.2%, which is below the sector average, suggesting competitive pressure.
At a current price of $19.39, KALV currently trades near the top of its 52-week range (83%) (Range: $9.83 - $21.30).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$993.20M
Trailing P/E
--
Forward P/E
19.28
Beta (5Y)
-0.40
52W High
$21.30
52W Low
$9.83
Avg Volume
952K
Day High
Day Low